TME PHARM.CONF.IPO EO 1- Tangible Net Worth Ratio
TME PHARM.CONF.IPO EO 1- tangible net worth ratio. TME PHARM.CONF.IPO EO 1- (0N6A) has a Tangible Net Worth Ratio of 99.8% as of December 2024. This metric is calculated by deducting intangible assets (€4.00K) from net assets (€1.61 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. See 0N6A equity financing ratio to measure how much of total assets are equity-financed.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Tangible Net Worth Ratio of TME PHARM.CONF.IPO EO 1- (2021–2024)
Tangible net worth ratio of TME PHARM.CONF.IPO EO 1- from 2021 to 2024. This chart shows how TME PHARM.CONF.IPO EO 1-'s Tangible Net Worth Ratio has changed across 2 annual periods from 2021 to 2024. As of December 2024, the ratio stands at 99.8%, reflecting net assets of €1.61 Million with intangible assets of €4.00K EUR. See 0N6A net working capital ratio to evaluate short-term liquidity relative to the company's equity base.
TME PHARM.CONF.IPO EO 1- Tangible Net Worth Ratio by Year (2021–2024)
TME PHARM.CONF.IPO EO 1- tangible net worth ratio by year from 2021 to 2024. The table below presents the year-by-year Tangible Net Worth Ratio for TME PHARM.CONF.IPO EO 1- from 2021 to 2024, covering 2 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. For live market cap and overall valuation, see market value of TME PHARM.CONF.IPO EO 1-.
| Year | Tangible NW Ratio | Net Assets (EUR) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 99.8% | €1.61 Million | €4.00K | €3.41 Million | ▼ -0.2 pp |
| 2021 | 99.9% | €4.50 Million | €4.00K | €9.77 Million | — |